about
Bone disease in thalassemia: a frequent and still unresolved problem.Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America.Pregnancy outcomes in women with thalassemia in North America and the United KingdomRelationship between chronic transfusion therapy and body composition in subjects with thalassemia.Renal dysfunction in patients with thalassaemiaQuality of life in thalassemia: a comparison of SF-36 results from the thalassemia longitudinal cohort to reported literature and the US norms.Hemoglobin H-constant spring in North America: an alpha thalassemia with frequent complications.Relationship among chelator adherence, change in chelators, and quality of life in thalassemia.A pilot study of subcutaneous decitabine in β-thalassemia intermediaRisk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network reportGuidelines for the Standard Monitoring of Patients With Thalassemia: Report of the Thalassemia Longitudinal Cohort.Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort.Increased leucocyte apoptosis in transfused β-thalassaemia patients.Iron chelation adherence to deferoxamine and deferasirox in thalassemia.Inadequate dietary intake in patients with thalassemiaBeliefs about chelation among thalassemia patients.Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertensionPain over time and its effects on life in thalassemia.Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia.Pain in thalassaemia: the effects of age on pain frequency and severity.Complications of beta-thalassemia major in North America.Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial.Pain as an emergent issue in thalassemia.
P50
Q33337925-20BF84D9-B3EF-4085-917A-5CD0BC0F0F92Q33559331-FC3A3E85-CD81-4152-AC9D-ECE4B6C5F0F4Q33930441-2C7A83F0-FC36-4D36-9EDC-D0D5C8F0098AQ34115891-80A45747-1448-4CB7-A0F2-3C616C96DBB7Q34601045-04875935-CCB0-49DB-81C7-930C6ECF146AQ34606415-E6A6A0A7-5731-476B-8236-CC435B9D9C86Q34626252-E1B58002-3040-4E27-A8A7-54FC80FA6E7CQ35043087-43269D6A-46D6-4409-9F10-803265F0E7D8Q35212344-E3C3457B-0FF5-436D-9979-473625165078Q35346284-2A5D5275-36DE-44B1-B6FE-F6B668D76DD5Q35881019-1F01D9EE-7C27-448A-A815-01C37A9F86F6Q35891598-D5A2B9DB-AB9C-4AA7-853F-049907D24481Q36136232-1793FF96-20A1-4741-8F6D-58B832BBA212Q36142495-60249CCA-5186-4C7B-B9F2-751007F77CD6Q36164903-97E8D721-9201-4CE8-8726-32B96011018EQ36535507-C5BF1F9A-3509-420A-9B42-4629B9A8B851Q37144856-B4551747-394F-44DE-903B-3D08B7EBF6E6Q37413453-1DD8E6B6-D2FA-4029-AF37-E7659F76C64DQ42979180-C6DBB385-FFCE-455E-86B6-CB48867F8FF4Q44274268-1F197FAB-07BE-4031-B680-7F9DBDE0C035Q44779180-B22F388A-7DE5-4C98-8361-A73A057258EBQ46602972-69E8D49F-9609-4C35-B7CC-17424CB13B31Q47106970-DE470805-409B-43A4-A4AD-C14851AD5A3D
P50
name
Thalassemia Clinical Research Network
@en
type
label
Thalassemia Clinical Research Network
@en
prefLabel
Thalassemia Clinical Research Network
@en